[ad_1]
The U.S. is making an attempt to dam a proposed $26 billion acquisition of Horizon Therapeutics by biotech drug developer Amgen on antitrust grounds.
The Federal Commerce Fee mentioned Tuesday that the deal, introduced in December, would give Amgen unfair leverage to dam competitors for Horizon medicines. The FTC mentioned the deal would entrench Horizon’s monopoly place on therapies for thyroid eye illness and continual refractory gout.
Amgen didn’t instantly reply to a request by The Related Press for remark.
The California firm mentioned in December that the acquisition would enable it to increase into uncommon illness therapies.
Horizon Therapeutics PLC, based mostly in Dublin, Eire, develops potential therapies for autoimmune and extreme inflammatory ailments. Its best-seller, Tepezza, is simply accepted in america and treats eye bulging and double imaginative and prescient from thyroid eye illness.
The FTC mentioned Tuesday that the deal would enable Amgen to make use of rebates on its current medicine to strain invoice payers like pharmacy profit managers into favoring Tepezz and Krystexxa, a remedy for continual refractory gout.
[ad_2]
Source link
